Zota Healthcare
Zota Healthcare
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
4- Stock is trading at 5.43 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -19.9% over last 3 years.
- Promoter holding has decreased over last 3 years: -18.7%
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoZota Health Care Ltd is a small-cap healthcare company with a market cap of ~₹4,970 Cr that has delivered strong revenue growth (85% TTM sales growth) but remains loss-making with a negative PE of -67.6 and a 3-year average ROE of -20%. The stock has appreciated significantly (57% CAGR over 3 years) despite persistent losses, creating a divergence between price momentum and fundamental profitability.
- TTM compounded sales growth of 85% indicates a sharp acceleration in revenue generation
- 3-year compounded sales CAGR of 57% shows sustained top-line momentum over a meaningful period
- 5-year compounded sales CAGR of 38% demonstrates a long-term revenue growth trajectory
- Stock price CAGR of 57% over 3 years reflects strong market confidence and re-rating
- 5-year stock price CAGR of 45% shows consistent long-term wealth creation for shareholders
- Company is expected to deliver a good upcoming quarter per available commentary
- 1-year stock price return of 20% indicates continued positive price momentum
- Negative PE ratio of -67.6 confirms the company is currently loss-making at the net profit level
- 3-year average ROE of -20% indicates sustained destruction of shareholder equity
- Last year ROE of -15% shows losses continue even as revenues grow rapidly, suggesting poor unit economics or high cost base
- TTM compounded profit declined by -22% even as sales grew 85%, indicating severe margin compression or rising losses
- Price-to-book ratio of 7.22x is elevated for a loss-making company with negative returns on equity
- Low interest coverage ratio suggests debt servicing is straining cash flows relative to operating earnings
- Promoter holding decreased by 1.25% in the last quarter, signalling potential insider caution
- Dividend yield of just 0.07% offers virtually no income cushion for shareholders bearing high equity risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago- 264 DavaIndia stores in Q1FY27 Jul 1
Zota opened 264 new DavaIndia pharmacy stores in Q1FY27, expanding total count from 2,579 to 2,825, showing strong retail network momentum.
- 80% acquisition of Globotask IT Jun 19
Signed MOU to acquire 80% of Globotask IT Consultancy for ₹25 lakh to secure in-house IT solutions for its growing operations.
- ₹2 Cr investment in Curexis Jun 22
Acquired 10 lakh equity shares of Curexis Ventures for ₹2 crore via rights issue to expand SKIA retail pharmacy stores.
- ₹2 Cr in Ugo Generic subsidiary Jun 22
Invested ₹2 crore in subsidiary KMHP Ventures (20 lakh shares) to launch retail stores under the new 'Ugo Generic' brand.
- FY26 shareholding disclosure filed Jun 15
Filed FY26 disclosure confirming no new encumbrances on promoter shares. Promoter group comprises 39 individuals and entities.
TL;DR: Zota Health Care is aggressively scaling its retail pharmacy footprint across multiple brands — DavaIndia (2,825 stores), SKIA, and the new Ugo Generic format — backed by small capital infusions into subsidiaries. No headwinds are visible in recent news, and there are no signs of financial stress with clean promoter shareholding. The trend is clearly expansion-oriented, though the capital-light investments (₹2 Cr each) suggest measured scaling rather than a large capex bet. Execution on multi-brand pharmacy rollout and IT integration will be key to watch in coming quarters.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 | 143 | 163 | 174 |
| Expenses | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 | 143 | 154 | 185 |
| Operating Profit | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 | 0 | 9 | -12 |
| OPM % | 3.3% | 10% | 7% | -3% | -2.2% | -1.3% | -8% | 2.5% | 3.8% | 4.9% | -0.3% | 5% | -7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | -3 | 2 |
| Interest | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 | 5 | 5 | 6 |
| Depreciation | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 | 22 | 27 | 28 |
| PBT | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 | -26 | -26 | -44 |
| Tax % | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% | 13% | 14% | -45% | 1% |
| Net Profit | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 | -30 | -14 | -44 |
| EPS in Rs | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.5 | -4.81 | -5.2 | -8.73 | -4.09 | -12.58 |
Profit & Loss
| Particulars | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 539 | 609 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 520 | 606 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 19 | 3 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 4.8% | 0.6% | 11% | 5% | 4.2% | -2% | 3.4% | 0.5% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 3 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 17 | 20 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 82 | 96 |
| PBT | 3 | 3 | 5 | 6 | 8 | 4 | 0 | 12 | -5 | -16 | -58 | -80 | -110 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | -7% | — |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | 0 | 9 | -6 | -14 | -57 | -74 | -104 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.7 | -21.35 | -30.6 |
| Div. Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1170% | 42% | -44% | -18% | -5% | -5% | — |
Balance Sheet
| Particulars | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 35 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 659 |
| Borrowings | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 270 |
| Other Liabilities | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 167 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 |
| Fixed Assets | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 383 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 2 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 264 |
| Other Assets | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 483 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 1,131 |
Cash Flow
| Particulars | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | 3 | 5 | -3 | 6 | -1 | 13 | -2 | -6 | -50 | -84 |
| Investing | — | — | -1 | -1 | 9 | -4 | 4 | -27 | 15 | -13 | -92 | -314 |
| Financing | — | — | -2 | -4 | -6 | -3 | -2 | 14 | -14 | 19 | 145 | 490 |
| Net Cash Flow | — | — | 0 | 0 | -1 | -1 | 1 | 1 | -1 | 0 | 3 | 92 |
| Free Cash Flow | — | — | 2 | 4 | -6 | -1 | -2 | 10 | -13 | -23 | -96 | -197 |
| CFO/OP | — | — | 78 | 81 | -12 | 147 | -134 | 115 | 2 | -59 | 811 | -394 |
Ratios
| Particulars | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 51 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 277 | 329 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 111 | 178 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 217 | 200 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 | 84 |
| ROCE % | — | 20% | — | 32% | — | 6% | -2% | 15% | -2% | -7% | -17% | -8% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Zota Healthcare insights
43 extracted metrics + investor summaries across FY11–FY26.
Documents
Frequently Asked Questions about Zota Healthcare
What does Zota Health Care Ltd do?
Where is Zota Health Care Ltd (ZOTA) listed?
Which sector does Zota Health Care Ltd belong to?
What is the market capitalisation of Zota Health Care Ltd?
What is the PE ratio of Zota Health Care Ltd?
What is the 52-week high and low of Zota Health Care Ltd?
Does Zota Health Care Ltd pay dividends?
What is the Return on Equity (ROE) of Zota Health Care Ltd?
Company Information
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZOTA.md for Zota Health Care Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.